Sign in

ANTX on Nasdaq

AN2 Therapeutics, Inc.

American pharmaceutical preparations company based in Menlo Park1

In its 2026 annual report the company says: “We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.”3 Its shares trade on Nasdaq under the symbol ANTX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerANTX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersMenlo Park, California1
  • Incorporated inDE2
  • Business address1300 El Camino Real, Suite 100, Menlo Park, Ca 940252
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

All brand names or trademarks appearing in this report are the property of their respective owners. Unless the context requires otherwise, references in this report to “ AN2,” “we,” “our,” the “Company” or the “Registrant” refer to AN2 Therapeutics.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$38.1M in 2025+77% since 2021
-$80.0M-$60.0M-$40.0M-$20.0M02021: -$21.6M-$21.6M20212022: -$42.3M-$42.3M2022+96%2023: -$69.6M-$69.6M2023+65%2024: -$56.8M-$56.8M2024−18%2025: -$38.1M-$38.1M2025−33%
Net income4567-$35.2M in 2025+63% since 2021
-$80.0M-$60.0M-$40.0M-$20.0M02021: -$21.5M-$21.5M20212022: -$41.0M-$41.0M2022+90%2023: -$64.7M-$64.7M2023+58%2024: -$51.3M-$51.3M2024−21%2025: -$35.2M-$35.2M2025−31%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development$24.8M$40.5M
General and administrative$13.3M$14.1M
Restructuring charges$2.2M
Total operating expenses$38.1M$56.8M
Loss from operations-$38.1M-$56.8M
Interest income$2.9M$5.5M
Other income$1.0K$1.0K
Net loss attributable to common stockholders-$35.2M-$51.3M
Net loss per share attributable to common stockholders, basic-$1.16-$1.72
Net loss per share attributable to common stockholders, diluted-$1.16-$1.72
Weighted-average number of shares used in computing net loss per share, basic30.2M shares29.8M shares
Weighted-average number of shares used in computing net loss per share, diluted30.2M shares29.8M shares
Unrealized gain (loss) on investments$26.0K-$244.0K
Comprehensive loss-$35.1M-$51.6M

Compare AN2 Therapeutics, Inc. with another company

Corporate structure

AN2 Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of AN2 Therapeutics, Inc.

  • AN2 Therapeutics, Inc. Menlo Park, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What AN2 Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$19.9M7 Dec 31, 2025$21.4M7 Dec 31, 2024−6.6%
Marketable securities, current$38.1M7 Dec 31, 2025$62.3M7 Dec 31, 2024−38.9%
Marketable securities, non-current$2.0M7 Dec 31, 2025$5.0M7 Dec 31, 2024−59.9%

Properties, in its own words

We operate primarily as a remote‑first organization. We do not own any real property. We use coworking or flexible office space in Menlo Park, California that serves as our registered address and for meetings or collaboration on an as-needed basis. We believe that our current facilities arrangement will be adequate for our near-term needs. If required, we believe that suitable space would be available in the future on commercially reasonable terms.

Item 2 of the 10-K filed Mar 17, 2026.3

Leadership

Who has led AN2 Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Eric Easom2022–now

Chief financial officer

  1. Lucy Day2022–now
2025
Board members and other officers (18)

Timeline

  1. Aug 11, 20268-K Results of operations29
  2. Jun 9, 20268-K Shareholder vote30
  3. Jun 4, 20268-K Regulation FD disclosure; Other events31
  4. May 11, 20268-K Results of operations32
  5. Apr 9, 20268-K Other events33
  6. Mar 20, 20268-K Executive or director change34
  7. Mar 17, 20268-K Results of operations35
  8. Mar 10, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure36
  9. Jan 29, 20268-K Executive or director change37
  10. Nov 12, 20258-K Results of operations38
  11. Aug 12, 20258-K Financial statements and exhibits39
  12. Jun 20, 20258-K Unregistered sale of shares40
  13. Mar 24, 2022New chief executive Eric Easom becomes CEO10

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202641

When it reported results

  1. Aug 11, 2026Reported quarterly or annual results29
  2. May 11, 2026Reported quarterly or annual results32
  3. Mar 17, 2026Reported quarterly or annual results35
  4. Nov 12, 2025Reported quarterly or annual results38
  5. Mar 25, 2025Reported quarterly or annual results42
  6. Nov 13, 2024Reported quarterly or annual results43
  7. Aug 13, 2024Reported quarterly or annual results44
  8. May 14, 2024Reported quarterly or annual results45

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

383 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 40 major events, 215 insider forms, 45 large holders, 1 private raises, 63 other. The latest 20:

  1. Oct 13, 20264 EDGAR
  2. Oct 13, 20264 EDGAR
  3. Oct 13, 20264 EDGAR
  4. Sep 16, 20264 EDGAR
  5. Sep 14, 2026S-8 EDGAR
  6. Sep 11, 20264 EDGAR
  7. Sep 8, 20264 EDGAR
  8. Sep 4, 20264 EDGAR
  9. Sep 2, 20264 EDGAR
  10. Aug 27, 20263 EDGAR
  11. Aug 19, 20264 EDGAR
  12. Aug 17, 2026144 EDGAR
  13. Aug 14, 20264 EDGAR
  14. Aug 11, 202610-Q EDGAR
  15. Aug 11, 20268-K EDGAR
  16. Jul 10, 20264 EDGAR
  17. Jul 10, 20264 EDGAR
  18. Jul 10, 20264 EDGAR
  19. Jul 10, 20264 EDGAR
  20. Jun 9, 20268-K EDGAR

The 383 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

97 open-market trades by officers, directors and large owners since October 2021: 29 buys and 68 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 9, 2026Readnour Robin ShaneDirectorSale1,108$6.02$6.7KForm 4
Sep 8, 2026Readnour Robin ShaneDirectorSale10,019$6.02$60.3KForm 4
Sep 3, 2026Readnour Robin ShaneDirectorSale6,100$6.07$37.0KForm 4
Sep 1, 2026Williams Sarah JoannePrincipal Accounting OfficerSale272$5.53$1.5KForm 4
Sep 1, 2026FitzPatrick Margaret MDirectorBuy2,098$5.53$11.6KForm 4
Aug 17, 2026Readnour Robin ShaneDirectorSale35,402$6.01$212.8KForm 4
Jul 8, 2026Eizen Joshua MSee RemarksSale5,945$4.17$24.8KForm 4
May 29, 2026Williams Sarah JoannePrincipal Accounting OfficerSale265$4.43$1.2KForm 4
Mar 3, 2026Williams Sarah JoannePrincipal Accounting OfficerSale327$1.06$347Form 4
Jan 6, 2026Day LucyChief Financial OfficerSale5,512$1.01$5.6KForm 4
Jan 6, 2026Prior Stephen DavidChief Strategy OfficerSale2,858$1.01$2.9KForm 4
Jan 6, 2026Chanda SanjayChief Development OfficerSale5,956$1.01$6.0KForm 4
Jan 6, 2026Eizen Joshua MSee RemarksSale6,931$1.01$7.0KForm 4
Jan 5, 2026Day LucyChief Financial OfficerSale3,295$1.00$3.3KForm 4
Jan 5, 2026Prior Stephen DavidChief Strategy OfficerSale3,604$1.00$3.6KForm 4
Jan 5, 2026Chanda SanjayChief Development OfficerSale3,295$1.00$3.3KForm 4
Jan 5, 2026Eizen Joshua MSee RemarksSale17,923$1.00$17.9KForm 4
Nov 4, 2025Eizen Joshua MSee RemarksSale2,819$1.14$3.2KForm 4
Nov 4, 2025Prior Stephen DavidChief Strategy OfficerSale765$1.14$872Form 4
Jun 2, 2025Easom EricChief Executive OfficerBuy10,000$1.07$10.7KForm 4

All 97 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Eric Easom58$603.8K$1.4M63
2025Josh Eizen49$450.0K$807.1K63
2025Lucy Day67$447.2K$774.3K63
2024PresidentChief Executive Officer and Board Chair$603.8K$1.7M63
2024Chief Legal Officer and Chief Operating Officer$435.4K$1.1M63
2024Chief Financial Officer$447.2K$812.7K63

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$40.0M 2026–2026
Money received by yearMoney received by year, 2026–2026: $40.0M in all. Private raises (Form D) $40.0M.$0$10M$20M$30M$40M2026 · Private raises (Form D): $40.0M2026
Figures by year
YearPrivate raises (Form D)Total
2026$40.0M$40.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Mar 10, 2026Raised $40 million in a private offering of equity64 Form D: 16 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 66. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vivo Capital, LLC3,153,640$15.3M1.4%No change
Commodore Capital LP2,933,680$14.2M0.8%+599,967
Millennium Management LLC2,318,692$11.2M0.0%+96,190
BlackRock, Inc.1,665,494$8.1M0.0%+1,346,726
Spruce Street Capital LP1,661,073$8.0M1.6%No change
Almitas Capital LLC1,469,129$7.1M1.7%−10,000
Vanguard Capital Management LLC1,238,705$6.0M0.0%+227,627
Adage Capital Partners Gp, L.l.c.1,000,000$4.8M0.0%No change
Citadel Advisors LLC951,997$4.6M0.0%+796,758
Boxer Capital Management, LLC749,035$3.6M0.3%No change
Geode Capital Management, LLC697,806$3.4M0.0%+411,259
SummitTX Capital, L.P.597,453$2.9M0.1%New
Balyasny Asset Management L.P.556,027$2.7M0.0%New
Stonepine Capital Management, LLC551,692$2.7M2.0%−162,153
Ameriprise Financial Inc537,064$2.6M0.0%−159,117
Sio Capital Management, LLC529,933$2.6M0.4%−127,267
Ally Bridge Group (NY) LLC526,315$2.5M3.3%No change
Prosight Management, LP474,638$2.3M0.4%−41,116
Woodline Partners LP459,805$2.2M0.0%−533,866
State Street Corp311,602$1.5M0.0%+196,400
Northern Trust Corp214,921$1.0M0.0%+171,725
Seven Fleet Capital Management LP208,946$1.0M0.2%+9,245
Vanguard Fiduciary Trust Co196,920$953.1K0.0%+59,212
Vanguard Portfolio Management LLC179,594$869.2K0.0%New
Landscape Capital Management, L.l.c.167,446$810.4K0.1%−130,720

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How AN2 Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAN2 Therapeutics, Inc.1
  • CIK0001880438
  • Employer ID (EIN)82-06066543
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1300 El Camino Real, Suite 100, Menlo Park, CA 940251
  • Phone(650) 331-90901
  • Shares outstanding37,736,237 as of Aug 6, 20269
  • Public float$23.1M as of Jun 30, 20253
  • AuditorPricewaterhouseCoopers LLP, San Jose, California PCAOB ID 238; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceSep 24, 20211
  • Filings384 in all: 4 (186), 8-K (40), 3 (21), SC 13G/A (15), 10-Q (14), 144 (14), SC 13G (12), SCHEDULE 13G/A (9)1
    All 37 form types

    4/A (7), S-8 (6), SCHEDULE 13G (6), 10-K (4), ARS (4), CORRESP (4), DEF 14A (4), DEFA14A (4), UPLOAD (4), 424B5 (3), EFFECT (3), 8-A12B (2), DRS/A (2), DRSLTR (2), S-3 (2), SCHEDULE 13D/A (2), SEC STAFF LETTER (2), 10-K/A (1), 3/A (1), 424B3 (1), 424B4 (1), CERT (1), D (1), DRS (1), PRE 14A (1), S-1 (1), S-1/A (1), S-1MEF (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 17, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Apr 22, 2026
    Latest 8-K (8-K) Aug 11, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.00001 per shareANTXThe Nasdaq Global Select Market

From the cover page of the 10-K filed Mar 17, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks AN2 Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 17, 2026: 70 risks under these headings, as written.3

  • Risks Related to Our Financial Position and Capital Needs
  • We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.
  • Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
  • We require substantial additional funding to meet our financial needs and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay, reduce or altogether cease our current and future product development programs or future commercialization efforts.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or to any of our product candidates.
  • We have a contractual commitment to develop epetraborole for global health initiatives, which may affect our ability to develop and commercialize epetraborole in certain countries and may impact our intellectual property rights. Our strategy for our global health initiatives depends on receiving non-dilutive funding, and we as a company have limited experience with this strategy.
  • Risks Related to the Development of Our Product Candidates
  • If we do not obtain regulatory approval for and successfully commercialize any of our product candidates, or if we experience significant delays in doing so, we may never become profitable.
  • We may not be successful in our efforts to build a pipeline of product candidates.
  • There can be no assurance that any clinical trials we conduct will be sufficient for product approval.
  • If clinical trials of our product candidates fail to demonstrate safety and/or efficacy of such product candidates to the satisfaction of the FDA or other comparable regulatory authorities, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
  • We cannot predict whether or when bacteria may develop resistance to any of our antibacterial product candidates, which could affect the revenue potential of our product candidates.
The other 60 risks
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential, or result in significant negative consequences following any potential regulatory approval.
  • If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.
  • If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities and receipt of necessary regulatory approvals could be delayed or prevented.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success.
  • Interim “topline” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We may conduct clinical trials for our product candidates outside of the U.S., and the FDA may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business.
  • Risks Related to Our Dependence on Third Parties
  • We rely on third parties to conduct our preclinical and nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain regulatory approval for or commercialize our product candidates may be delayed.
  • Our reliance on single-sourced third parties to manufacture our product candidates increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
  • Evaluation of our product candidates in investigator-initiated clinical trials (“IITs”) may expose us to additional risks that could impair the development of our product candidates.
  • Risks Related to the Commercialization of Our Product Candidates
  • Even if any of our product candidates receive regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • If we are unable to establish sales, marketing and distribution capabilities for our product candidates, or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates, if and when they are approved.
  • Coverage and adequate reimbursement may not be available for any of our product candidates, which could make it difficult for us to sell profitably, if approved.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • There are a variety of risks associated with marketing our product candidates internationally, which could affect our business.
  • Risks Related to Our Business, Industry and Managing Our Growth
  • We operate with a small team and our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
  • Macroeconomic uncertainties have in the past and may continue to adversely impact our business, financial condition, results of operations and growth prospects.
  • We have identified material weaknesses in our internal control over financial reporting. Due to our failure to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.
  • If in the future, we need to expand our research, development, and business capabilities and implement sales, marketing, and distribution capabilities, we may encounter difficulties in managing such growth, which could disrupt our operations.
  • If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and maintain patent and other intellectual property protection for our technology, or for our product candidates, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be impaired.
  • Our rights to develop and commercialize our technology and our other product candidates are subject, in large part, to the terms and conditions of licenses granted to us by others, such as Anacor. If we fail to comply with our obligations in the agreements under which we in-license or acquire development or commercialization rights to products, technology, or data from third parties, we could lose such rights that are important to our business.
  • We may not be successful in obtaining necessary rights to any product candidates we may develop through acquisitions and in-licenses.
  • We may become involved in lawsuits to protect or enforce our owned or in-licensed patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.
  • Third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business.
  • We may be subject to claims by third parties asserting that we or our employees, consultants and advisors have misappropriated their intellectual property rights or claiming ownership of what we regard as our own intellectual property rights.
  • Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.
  • If we are unable to protect the confidentiality of our proprietary information, know-how and trade secrets, the value of our product candidates could be adversely affected and our business and competitive position would be harmed.
  • If we or our licensors do not obtain patent term extension and data exclusivity for any product candidates we or our licensors may develop, our business may be materially harmed.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
  • If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.
  • Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
  • We may not be able to obtain or maintain orphan drug designations for any product candidates, and we may be unable to take advantage of the benefits associated with orphan drug designation, including the potential for market exclusivity.
  • We may attempt to seek accelerated approval in the U.S. for certain of our product candidates. If we are not able to use that pathway, we may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, necessary regulatory approvals, if we receive them at all. In addition, even if an accelerated approval pathway is available to us, it may not lead to expedited approval of our product candidates, or approval at all.
  • Failure to obtain regulatory approval in foreign jurisdictions would prevent our product candidates from being marketed in these territories. Any approval we are granted for our product candidates in the U.S. would not assure approval of such product candidates in foreign jurisdictions.
  • Even if we obtain regulatory approvals for our product candidates, the terms of approvals and ongoing regulation of such product candidates may limit how we manufacture and market the product candidates and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • Our employees, independent contractors, principal investigators, CROs, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • If we successfully commercialize any of our product candidates, failure to comply with our reporting and payment obligations under U.S. governmental pricing programs could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
  • Our current and future relationships with healthcare professionals, principal investigators, consultants, customers, and third-party payors in the U.S. and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency and other healthcare laws and regulations, which could expose us to penalties.
  • Changes in healthcare policies, laws, and regulations may impact our ability to obtain approval for, or commercialize our product candidates, if approved.
  • We are subject to privacy and data security laws, rules, regulations, policies, industry standards, and contractual obligations, and our failure to comply with them could harm our business.
  • We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
  • Risks Related to Ownership of Our Common Stock
  • Concentration of ownership of our common stock among our existing executive officers, directors, and principal stockholders may prevent new investors from influencing significant corporate decisions and matters submitted to stockholders for approval.
  • A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.
  • Provisions in our corporate charter documents and under Delaware law, and the adoption of a rights plan, could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
  • Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the U.S. will be the exclusive forums for substantially all disputes between us and our stockholders, including claims under the Securities Act, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • We will have broad discretion in the use of our cash, and may invest or spend our cash in ways with which you do not agree and in ways that may not increase the value of your investment.
  • We do not anticipate paying any cash dividends on our capital stock in the foreseeable future, and accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • General Risk Factors
  • The trading price of our common stock has been and may continue to be volatile.
  • If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline.
  • We are incurring significantly increased costs as a result of operating as a company whose common stock is publicly traded in the U.S., and our management is devoting substantial time to new compliance initiatives.
  • Significant disruptions of our or our vendors’ information technology systems or cybersecurity incidents could result in significant financial, legal, regulatory, business, and reputational harm to us.
  • We are an “emerging growth company” and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.
  • If we fail to adhere to the listing requirements of the Nasdaq Global Select Market our common stock could be delisted.
  • Recent and potential future changes to U.S. and non-U.S. tax laws could materially adversely affect our company.
  • Indemnity provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection, and other losses.

Legal proceedings

The information in Part IV, Note 7—Commitments and Contingencies—Contingencies is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64